Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

montelukast

- PMLiVE

More good news, and some bad, for Merck’s Keytruda

A rare setback in phase 3 liver cancer trial

- PMLiVE

Merck puts prostate cancer firmly in Keytruda’s sights

Lynparza combination could open up huge new market

- PMLiVE

Analysts look beyond Keytruda in Merck’s future

CEO Frazier made to defend pipeline prospects

- PMLiVE

Merck’s backing of NGM Bio yields NASH drug deal

Drug has potential in diabetes treatment as well

- PMLiVE

AstraZeneca wins NICE backing for asthma injection

NICE hails 'competitive pharma market'

- PMLiVE

Merck exec steps down, two takes his place

Head of global human health Adam Schechter will transition to CEO advisor

- PMLiVE

MSD claims EU approval for two HIV products

Company battles back against dominant Gilead and GSK

Sanofi reception

Dupixent helps put Sanofi back on growth track

French drugs giant sees an 8% rise in vaccine sales

- PMLiVE

Keytruda hits survival targets in first-line kidney cancer

New data presented at ESMO congress

- PMLiVE

Merck & Co picks Nike exec to be digital transformation leader

Cyber-security and customer focus will be key issues

AstraZeneca AZ

AZ, Amgen’s first-in-class asthma drug gets breakthrough status

Clinical data from the TSLP targeting antibody is due in 2020

- PMLiVE

Merck & Co joins big pharma pricing pledge – but sceptics unconvinced

Large portfolios gives companies room for manoeuvre

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links